Literature DB >> 23338609

The planar cell polarity pathway drives pathogenesis of chronic lymphocytic leukemia by the regulation of B-lymphocyte migration.

Markéta Kaucká1, Karla Plevová, Sárka Pavlová, Pavlína Janovská, Archana Mishra, Jan Verner, Jirina Procházková, Pavel Krejcí, Jana Kotasková, Petra Ovesná, Boris Tichy, Yvona Brychtová, Michael Doubek, Alois Kozubík, Jirí Mayer, Sárka Pospísilová, Vítezslav Bryja.   

Abstract

The planar cell polarity (PCP) pathway is a conserved pathway that regulates cell migration and polarity in various contexts. Here we show that key PCP pathway components such as Vangl2, Celsr1, Prickle1, FZD3, FZD7, Dvl2, Dvl3, and casein kinase 1 (CK1)-ε are upregulated in B lymphocytes of patients with chronic lymphocytic leukemia (CLL). Elevated levels of PCP proteins accumulate in advanced stages of the disease. Here, we show that PCP pathway is required for the migration and transendothelial invasion of CLL cells and that patients with high expression of PCP genes, FZD3, FZD7, and PRICKLE1, have a less favorable clinical prognosis. Our findings establish that the PCP pathway acts as an important regulator of CLL cell migration and invasion. PCP proteins represent an important class of molecules regulating pathogenic interaction of CLL cells with their microenvironment. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23338609     DOI: 10.1158/0008-5472.CAN-12-1752

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

Review 1.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors:  Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

2.  Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer.

Authors:  Martin Pichler; Cristian Rodriguez-Aguayo; Su Youn Nam; Mihnea Paul Dragomir; Recep Bayraktar; Simone Anfossi; Erik Knutsen; Cristina Ivan; Enrique Fuentes-Mattei; Sang Kil Lee; Hui Ling; Tina Catela Ivkovic; Guoliang Huang; Li Huang; Yoshinaga Okugawa; Hiroyuki Katayama; Ayumu Taguchi; Emine Bayraktar; Rajat Bhattacharya; Paola Amero; William Ruixian He; Anh M Tran; Petra Vychytilova-Faltejskova; Christiane Klec; Diana L Bonilla; Xinna Zhang; Sanja Kapitanovic; Bozo Loncar; Roberta Gafà; Zhihui Wang; Vittorio Cristini; Samir M Hanash; Menashe Bar-Eli; Giovanni Lanza; Ondrej Slaby; Ajay Goel; Isidore Rigoutsos; Gabriel Lopez-Berestein; George Adrian Calin
Journal:  Gut       Date:  2020-01-27       Impact factor: 23.059

3.  WNT5A: a motility-promoting factor in Hodgkin lymphoma.

Authors:  F Linke; S Zaunig; M M Nietert; F von Bonin; S Lutz; C Dullin; P Janovská; T Beissbarth; F Alves; W Klapper; V Bryja; T Pukrop; L Trümper; J Wilting; D Kube
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

Review 4.  Vangl1 and Vangl2: planar cell polarity components with a developing role in cancer.

Authors:  Jason Hatakeyama; Jessica H Wald; Ignat Printsev; Hsin-Yi Henry Ho; Kermit L Carraway
Journal:  Endocr Relat Cancer       Date:  2014-06-30       Impact factor: 5.678

5.  The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting.

Authors:  T Vaisitti; V Audrito; S Serra; R Buonincontri; G Sociali; E Mannino; A Pagnani; A Zucchetto; E Tissino; C Vitale; M Coscia; C Usai; C Pepper; V Gattei; S Bruzzone; S Deaglio
Journal:  Leukemia       Date:  2014-07-03       Impact factor: 11.528

6.  Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer.

Authors:  Andrii Monastyrskyi; Napon Nilchan; Victor Quereda; Yoshihiko Noguchi; Claudia Ruiz; Wayne Grant; Michael Cameron; Derek Duckett; William Roush
Journal:  Bioorg Med Chem       Date:  2017-12-15       Impact factor: 3.641

Review 7.  The physiological role of Wnt pathway in normal development and cancer.

Authors:  Xiang Li; Maria A Ortiz; Leszek Kotula
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-29

8.  Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton.

Authors:  P B Knudsen; B Hanna; S Ohl; L Sellner; T Zenz; H Döhner; S Stilgenbauer; T O Larsen; P Lichter; M Seiffert
Journal:  Leukemia       Date:  2013-11-27       Impact factor: 11.528

9.  Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL.

Authors:  Lili Wang; Alex K Shalek; Mike Lawrence; Ruihua Ding; Jellert T Gaublomme; Nathalie Pochet; Petar Stojanov; Carrie Sougnez; Sachet A Shukla; Kristen E Stevenson; Wandi Zhang; Jessica Wong; Quinlan L Sievers; Bryan T MacDonald; Alexander R Vartanov; Natalie R Goldstein; Donna Neuberg; Xi He; Eric Lander; Nir Hacohen; Aviv Regev; Gad Getz; Jennifer R Brown; Hongkun Park; Catherine J Wu
Journal:  Blood       Date:  2014-04-28       Impact factor: 22.113

10.  Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness.

Authors:  Monica Messina; Ilaria Del Giudice; Hossein Khiabanian; Davide Rossi; Sabina Chiaretti; Silvia Rasi; Valeria Spina; Antony B Holmes; Marilisa Marinelli; Giulia Fabbri; Alfonso Piciocchi; Francesca R Mauro; Anna Guarini; Gianluca Gaidano; Riccardo Dalla-Favera; Laura Pasqualucci; Raul Rabadan; Robin Foà
Journal:  Blood       Date:  2014-02-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.